2. Search Result
Search Result
Pathways Recommended: Neuronal Signaling Cell Cycle/DNA Damage
Results for "

neuronal damage

" in MedChemExpress (MCE) Product Catalog:

59

Inhibitors & Agonists

3

Peptides

1

Inhibitory Antibodies

19

Natural
Products

7

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-155126
    LZWL02003

    		Reactive Oxygen Species Neurological Disease
    LZWL02003 is an anti-neuroinflammatory agent. LZWL02003 has protective effect on MPP +-induced neuronal damage, and reduces the expression of ROS. LZWL02003 improves cognition, memory, learning, and athletic ability in a Rotenone (HY-B1756)-induced PD rat model. LZWL02003 can be used for research of neurodegenerative disease .
    LZWL02003
  • HY-N6669
    Methyl 3-O-methylgallate
    1 Publications Verification

    M3OMG

    		 Others Neurological Disease
    Methyl 3-O-methylgallate (M3OMG) possesses antioxidant effect and can protect neuronal cells from oxidative damage .
    Methyl 3-O-methylgallate
  • HY-120875
    HX600

    		RAR/RXR Neurological Disease
    HX600 is a synthetic agonist for RXR (Retinoid X Receptor) heterodimer complex. HX600 prevents ischemia-induced neuronal damage. HX600 has orally bioactivity .
    HX600
  • HY-108038
    ABT-107

    		nAChR Neurological Disease
    ABT-107 is a selective α7 neuronal nicotinic receptor agonist. ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions .
    ABT-107
  • HY-100807
    Quinolinic acid
    5 Publications Verification

    		 Endogenous Metabolite iGluR Neurological Disease Inflammation/Immunology
    Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction .
    Quinolinic acid
  • HY-P5883
    TAT-M2NX

    tatM2NX

    		 TRP Channel Neurological Disease
    TAT-M2NX (tatM2NX) is a TRPM2 inhibitor with specific neuroprotective activity in male mice. TAT-M2NX can be used to study ischemic neuronal damage .
    TAT-M2NX
  • HY-P3780
    Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42)

    		Amyloid-β Neurological Disease
    Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42) is the 36-42 fragment of Amyloid β-Protein. β-amyloid, a polypeptide made up of 36-43 amino acids, is the main component of amyloid plaques found in the brains of people with Alzheimer's disease. β-amyloid oligomers (Aβos) plays A key role in the progression of Alzheimer's disease (AD) by inducing neuronal damage and cognitive impairment .
    Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42)
  • HY-111499
    Emopamil

    		Endogenous Metabolite Calcium Channel Neurological Disease
    Emopamil is an inhibitor of calcium channel that can reduce ischemia-induced neuronal cell damage .
    Emopamil
  • HY-N10283
    Neoechinulin C

    		Endogenous Metabolite Neurological Disease
    Neoechinulin C, an echinulin-related indolediketopiperazine alkaloid, protects the neuronal cells against paraquat-induced damage in a Parkinson’s disease model .
    Neoechinulin C
  • HY-162385
    COX-2-IN-42

    		COX Inflammation/Immunology
    COX-2-IN-42 (Compound T1) is a COX-2 inhibitor, and protects zebrafish against PTZ-induced neuronal damage .
    COX-2-IN-42
  • HY-113772
    Inflachromene

    		NF-κB ERK JNK p38 MAPK Neurological Disease Inflammation/Immunology
    Inflachromene, a microglial inhibitor, binds to HMGB1 and HMGB2 and exerts anti-inflammatory effects. Inflachromene effectively downregulates proinflammatory functions of HMGB and reduces neuronal damage. Inflachromene can be used for the research of neuroinflammatory disorders .
    Inflachromene
  • HY-N4098
    Incensole Acetate

    		Apoptosis Neurological Disease
    Incensole acetate is a main constituent of Boswellia carterii resin, has neuroprotective effects against neuronal damage in traumatic and ischemic head injury. Incensole acetate reduces Aβ25–35-triggered apoptosis in hOBNSCs .
    Incensole Acetate
  • HY-B0927
    Hydrastine

    (-)-β-Hydrastine; (1R,9S)-β-Hydrastine

    		 Tyrosine Hydroxylase Dopamine Receptor OAT Neurological Disease
    Hydrastine ((-)-β-Hydrastine; (1R,9S)-β-Hydrastine) is a selective competitive inhibitor of tyrosine hydroxylase (TH), inhibiting dopamine biosynthesis (IC50=20.7 μM, PC12 cells). Hydrastine also inhibits the organic cation transporter OCT1 (IC50=6.6 μM). Hydrastine may cause neuronal toxicity through mitochondrial dysfunction rather than oxidative stress damage, and can aggravate cell apoptosis when combined with L-DOPA. Hydrastine can be used to study Parkinson's disease-related dopaminergic neuronal damage .
    Hydrastine
  • HY-133712
    Yonkenafil

    Tunodafil

    		 Phosphodiesterase (PDE) Neurological Disease
    Yonkenafil (Tunodafil), a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease .
    Yonkenafil
  • HY-100807S2
    Quinolinic acid-13C4,15N

    		Endogenous Metabolite Neurological Disease Inflammation/Immunology
    Quinolinic acid-13C4, 15N is an isotopic labeled Quinolinic acid (HY-100807). Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist and has the potential of mediating NMDA neuronal damage and dysfunction .
    Quinolinic acid-13C4,15N
  • HY-125095
    Yonkenafil hydrochloride

    Tunodafil hydrochloride

    		 Phosphodiesterase (PDE) Cardiovascular Disease Neurological Disease
    Yonkenafil (Tunodafil) hydrochloride, a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil (Tunodafil) hydrochloride may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease .
    Yonkenafil hydrochloride
  • HY-120553
    B-355252

    		Apoptosis Neurological Disease
    B355252, a phenoxy thiophene sulfonamide small molecule, is a potent NGF receptor agonist. B355252 potentiates NGF-induced neurite outgrowth. B355252 protects ischemic neurons from neuronal loss by attenuating DNA damage, reducing ROS production and the LDH level, and preventing neuronal apoptosis. B355252 has anti-apoptotic effects in glutamate-induced excitotoxicity, as well as in a murine hippocampal cell line (HT22) model of Parkinson disease (PD) .
    B-355252
  • HY-B0927R
    Hydrastine (Standard)

    (-)-β-Hydrastine (Standard); (1R,9S)-β-Hydrastine (Standard)

    		 Reference Standards Tyrosine Hydroxylase Dopamine Receptor OAT Others
    Hydrastine (Standard) is the analytical standard of Hydrastine (HY-B0927). This product is intended for research and analytical applications. Hydrastine ((-)-β-Hydrastine; (1R,9S)-β-Hydrastine) is a selective competitive inhibitor of tyrosine hydroxylase (TH), inhibiting dopamine biosynthesis (IC50=20.7 μM, PC12 cells). Hydrastine also inhibits the organic cation transporter OCT1 (IC50=6.6 μM). Hydrastine may cause neuronal toxicity through mitochondrial dysfunction rather than oxidative stress damage, and can aggravate cell apoptosis when combined with L-DOPA. Hydrastine can be used to study Parkinson's disease-related dopaminergic neuronal damage .
    Hydrastine (Standard)
  • HY-14314
    ABT-418

    		Endogenous Metabolite Neurological Disease
    ABT-418 is a selective neuronal nicotinic acetylcholine receptor ligand with activity in improving spatial memory. ABT-418 administered before training can significantly reduce the spatial discrimination deficit caused by ventricular damage. ABT-418 is considered to be a potential treatment for attention deficit disorder .
    ABT-418
  • HY-100807S
    Quinolinic acid-d3

    		Endogenous Metabolite iGluR Neurological Disease Inflammation/Immunology
    Quinolinic acid-d3 is the deuterium labeled Quinolinic acid. Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction[1][2].
    Quinolinic acid-d3
  • HY-100807R
    Quinolinic acid (Standard)
    5 Publications Verification

    		 Reference Standards Endogenous Metabolite iGluR Neurological Disease Inflammation/Immunology
    Quinolinic acid (Standard) is the analytical standard of Quinolinic acid. This product is intended for research and analytical applications. Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction .
    Quinolinic acid (Standard)
  • HY-N4098R
    Incensole Acetate (Standard)

    		Apoptosis Neurological Disease
    Incensole Acetate (Standard) is the analytical standard of Incensole Acetate. This product is intended for research and analytical applications. Incensole acetate is a main constituent of Boswellia carterii resin, has neuroprotective effects against neuronal damage in traumatic and ischemic head injury. Incensole acetate reduces Aβ25–35-triggered apoptosis in hOBNSCs .
    Incensole Acetate (Standard)
  • HY-100807S1
    Quinolinic acid-13C7

    		Isotope-Labeled Compounds iGluR Endogenous Metabolite Others
    Quinolinic acid- 13C7 is the 13C labeled Quinolinic acid (HY-100807) . Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction .
    Quinolinic acid-13C7
  • HY-113410
    3-Methylglutaric acid

    		Na+/K+ ATPase Mitochondrial Metabolism Reactive Oxygen Species Neurological Disease Metabolic Disease
    3-Methylglutaric acid is a non-selective inhibitor of mitochondrial function and Na +, K +-ATPase, with an inhibition rate of 30% on rat cortical synaptosomal Na +, K +-ATPase. 3-Methylglutaric acid can induce reactive oxygen species (ROS) generation, thereby causing oxidative damage and inhibiting mitochondrial redox potential and ion pump function of cell membranes. 3-Methylglutaric acid can be used to study the neuropathological mechanisms of metabolic diseases and the role of oxidative stress-mediated neuronal damage in neurodegeneration .
    3-Methylglutaric acid
  • HY-118700
    2-Iminobiotin

    Guanidinobiotin

    		 NO Synthase Neurological Disease
    2-Iminobiotin (Guanidinobiotin) is a biotin (vitamin H or B7) analog. 2-Iminobiotin is a reversible nitric oxide synthases inhibitor with Kis of 21.8 and 37.5μM for murine iNOS and rat n-cNOS, respectively . 2-Iminobiotin superimposes on hypothermia protects human neuronal cells from hypoxia-induced cell damage .
    2-Iminobiotin
  • HY-107343
    Docosahexaenoic acid ethyl ester

    Ethyl docosahexaenoate

    		 Others Neurological Disease Metabolic Disease
    Docosahexaenoic acid ethyl ester (Ethyl docosahexaenoate) is a 90% concentrated ethyl ester of docosahexaenoic acid manufactured from the microalgal oil. Docosahexaenoic acid ethyl ester enhances 6-hydroxydopamine-induced neuronal damage by induction of lipid peroxidation in mouse striatum. Docosahexaenoic acid (DHA) is a key component of the cell membrane, and its peroxidation is inducible due to the double-bond chemical structure. Docosahexaenoic acid has neuroprotective effects .
    Docosahexaenoic acid ethyl ester
  • HY-N6967
    Levomenol

    (-)-α-Bisabolol

    		 Apoptosis Neurological Disease Inflammation/Immunology
    Levomenol ((-)-α-Bisabolol), a monocyclic sesquiterpene alcohol, exerts antioxidant, anti-inflammatory, and anti-apoptotic activities. Levomenol also has neuroprotective effects and prevents neuronal damage and memory deficits through reduction of proinflammatory markers induced by permanent focal cerebral ischemia in mice. Levomenol attenuates nociceptive behaviour and central sensitisation in a rodent model of trigeminal neuropathic pain. Orally active .
    Levomenol
  • HY-P10360
    Tat-βsyn-degron

    		α-synuclein Neurological Disease
    Tat-βsyn-degron is an α-synuclein knockdown peptide that effectively degrades α-synuclein protein via the proteasome pathway. Tat-βsyn-degron effectively reduces α-synuclein protein levels in primary rat cortical neuron cultures. In a Parkinson's mouse toxicity model, Tat-βsyn-degron can alleviate parkinsonian toxin-induced neuronal damage and movement disorders .
    Tat-βsyn-degron
  • HY-B1142
    Lipoamide
    5+ Cited Publications

    (±)-α-Lipoamide; DL-Lipoamide; DL-6,8-Thioctamide

    		 NO Synthase Others
    Lipoamide ((±)-α-Lipoamide) is a monocarboxylic acid derivative of a neutral amide, formed by the condensation of the carboxyl group of lipoic acid and ammonia. Lipoamide protects against oxidative stress-mediated neuronal cell damage and also acts as a coenzyme to transfer acetyl groups and hydrogen during pyruvate deacylation. Lipoamide also stimulates mitochondrial biogenesis in adipocytes through the endothelial NO synthase-cGMP-protein kinase G signaling pathway .
    Lipoamide
  • HY-118700A
    2-Iminobiotin hydrobromide

    Guanidinobiotin hydrobromide

    		 NO Synthase Neurological Disease
    2-Iminobiotin hydrobromide (Guanidinobiotin hydrobromide) is a biotin (vitamin H or B7) analog. 2-Iminobiotin hydrobromide is a reversible nitric oxide synthases inhibitor with Kis of 21.8 and 37.5 μM for murine iNOS and rat n-cNOS, respectively . 2-Iminobiotin hydrobromide superimposes on hypothermia protects human neuronal cells from hypoxia-induced cell damage .
    2-Iminobiotin hydrobromide
  • HY-170790
    HZS60

    		TRP Channel Neurological Disease
    HZS60 is a NMDAR/TRPM4 inhibitor with brain permeability that can improve cerebral ischemia. HZS60 has significant neuroprotective effects on primary neuronal ischemic damage caused by NMDA and oxygen-glucose deprivation/reoxygenation. HZS60 exhibits good pharmacokinetic characteristics and can inhibit cerebral ischemia-reperfusion injury. HZS60 can be used as a potential inhibitor of ischemic stroke .
    HZS60
  • HY-P99797
    Pabinafusp alfa

    JR-141

    		 Transferrin Receptor Neurological Disease
    Pabinafusp alfa (JR-141) is a transferrin receptor-targeting antibody consisting of Iduronate 2-sulfatase (HY-P76399) and an anti-human transferrin receptor antibody. Pabinafusp alfa is blood-brain permeable and prevents heparan sulfate (HS) deposition in the central nervous system of mucopolysaccharidosis II (MPS II) mice. Pabinafusp alfa improves learning and prevents central nervous system neuronal damage in mice .
    Pabinafusp alfa
  • HY-111093
    Protein kinase inhibitor 8

    		CaMK Neurological Disease
    Protein kinase inhibitor 8 (Compound CK59) is a calmodulin-dependent protein kinase II (CaMKII) inhibitor. By inhibiting the activity of CaMKII, Protein kinase inhibitor 8 can attenuate the cytotoxicity induced by perfluorooctane sulfonic acid (PFOS) and alleviate the downregulation of GLT-1 expression caused by PFOS, thereby reducing neuronal damage. Protein kinase inhibitor 8 may be useful in research related to neurodegenerative diseases .
    Protein kinase inhibitor 8
  • HY-113410S
    3-Methylglutaric acid-d4

    		Isotope-Labeled Compounds Na+/K+ ATPase Mitochondrial Metabolism Reactive Oxygen Species Neurological Disease Metabolic Disease
    3-Methylglutaric acid-d4 is the deuterium labeled 3-Methylglutaric acid (HY-113410). 3-Methylglutaric acid is a non-selective inhibitor of mitochondrial function and Na +, K +-ATPase, with an inhibition rate of 30% on rat cortical synaptosomal Na +, K +-ATPase. 3-Methylglutaric acid can induce reactive oxygen species (ROS) generation, thereby causing oxidative damage and inhibiting mitochondrial redox potential and ion pump function of cell membranes. 3-Methylglutaric acid can be used to study the neuropathological mechanisms of metabolic diseases and the role of oxidative stress-mediated neuronal damage in neurodegeneration .
    3-Methylglutaric acid-d4
  • HY-113410R
    3-Methylglutaric acid (Standard)

    		Na+/K+ ATPase Mitochondrial Metabolism Reactive Oxygen Species Neurological Disease Metabolic Disease
    3-Methylglutaric acid (Standard) is the analytical standard of 3-Methylglutaric acid (HY-113410). This product is intended for research and analytical applications. 3-Methylglutaric acid is a non-selective inhibitor of mitochondrial function and Na +, K +-ATPase, with an inhibition rate of 30% on rat cortical synaptosomal Na +, K +-ATPase. 3-Methylglutaric acid can induce reactive oxygen species (ROS) generation, thereby causing oxidative damage and inhibiting mitochondrial redox potential and ion pump function of cell membranes. 3-Methylglutaric acid can be used to study the neuropathological mechanisms of metabolic diseases and the role of oxidative stress-mediated neuronal damage in neurodegeneration .
    3-Methylglutaric acid (Standard)
  • HY-N7046
    Silybin B

    Silibinin B

    		 Amyloid-β Apoptosis JNK p38 MAPK Neurological Disease Cancer
    Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .
    Silybin B
  • HY-125039
    N-Acetyl lysyltyrosylcysteine amide
    2 Publications Verification

    		 Glutathione Peroxidase Cardiovascular Disease Neurological Disease
    N-Acetyl lysyltyrosylcysteine amide is a potent, reversible, specific, and non-toxic tripeptide inhibitor of myeloperoxidase (MPO). N-Acetyl lysyltyrosylcysteine amide effectively inhibits MPO generation of toxic oxidants in vivo. N-Acetyl lysyltyrosylcysteine amide reduces neuronal damage and preserves brain tissue and neurological function in the stroked brain. N-Acetyl lysyltyrosylcysteine amide inhibits MPO-dependent hypochlorous acid (HOCl) generation, protein nitration, and LDL oxidation .
    N-Acetyl lysyltyrosylcysteine amide
  • HY-107343R
    Docosahexaenoic acid ethyl ester (Standard)

    		Endogenous Metabolite Neurological Disease Metabolic Disease
    Docosahexaenoic acid ethyl ester (Standard) is the analytical standard of Docosahexaenoic acid ethyl ester. This product is intended for research and analytical applications. Docosahexaenoic acid ethyl ester (Ethyl docosahexaenoate) is a 90% concentrated ethyl ester of docosahexaenoic acid manufactured from the microalgal oil. Docosahexaenoic acid ethyl ester enhances 6-hydroxydopamine-induced neuronal damage by induction of lipid peroxidation in mouse striatum. Docosahexaenoic acid (DHA) is a key component of the cell membrane, and its peroxidation is inducible due to the double-bond chemical structure. Docosahexaenoic acid has neuroprotective effects .
    Docosahexaenoic acid ethyl ester (Standard)
  • HY-107343S
    Docosahexaenoic acid ethyl ester-d5

    Ethyl docosahexaenoate-d5

    		 Isotope-Labeled Compounds Neurological Disease Metabolic Disease
    Docosahexaenoic acid ethyl ester-d5 is the deuterium labeled Docosahexaenoic acid ethyl ester. Docosahexaenoic acid ethyl ester (Ethyl docosahexaenoate) is a 90% concentrated ethyl ester of docosahexaenoic acid manufactured from the microalgal oil. Docosahexaenoic acid ethyl ester enhances 6-hydroxydopamine-induced neuronal damage by induction of lipid peroxidation in mouse striatum. Docosahexaenoic acid (DHA) is a key component of the cell membrane, and its peroxidation is inducible due to the double-bond chemical structure. Docosahexaenoic acid has neuroprotective effects[1][2].
    Docosahexaenoic acid ethyl ester-d5
  • HY-107343S1
    Docosahexaenoic acid ethyl ester-d5-1

    Ethyl docosahexaenoate-d5-1

    		 Isotope-Labeled Compounds Others
    Docosahexaenoic acid ethyl ester-d5-1 is the deuterium labeled Docosahexaenoic acid ethyl ester. Docosahexaenoic acid ethyl ester (Ethyl docosahexaenoate) is a 90% concentrated ethyl ester of docosahexaenoic acid manufactured from the microalgal oil. Docosahexaenoic acid ethyl ester enhances 6-hydroxydopamine-induced neuronal damage by induction of lipid peroxidation in mouse striatum. Docosahexaenoic acid (DHA) is a key component of the cell membrane, and its peroxidation is inducible due to the double-bond chemical structure. Docosahexaenoic acid has neuroprotective effects[1][2][3].
    Docosahexaenoic acid ethyl ester-d5-1
  • HY-124293
    AA147
    4 Publications Verification

    		 ATF6 Reactive Oxygen Species Neurological Disease Metabolic Disease
    AA147 is a endoplasmic reticulum (ER) proteostasis regulator. AA147 promotes protection against oxidative damage in neuronal cells and prevents endothelial barrier dysfunction by activating ATF6 arm (selectively) of the unfolded protein response (UPR) and the NRF2 oxidative stress response. AA147 can rebalances XBP1s expression in vivo, and also induces survival motor neuron (SMN) expression and spinal motorneuron (MN) protection .
    AA147
  • HY-N6967R
    Levomenol (Standard)

    		Apoptosis Neurological Disease Inflammation/Immunology
    Levomenol (Standard) is the analytical standard of Levomenol. This product is intended for research and analytical applications. Levomenol ((-)-α-Bisabolol), a monocyclic sesquiterpene alcohol, exerts antioxidant, anti-inflammatory, and anti-apoptotic activities. Levomenol also has neuroprotective effects and prevents neuronal damage and memory deficits through reduction of proinflammatory markers induced by permanent focal cerebral ischemia in mice. Levomenol attenuates nociceptive behaviour and central sensitisation in a rodent model of trigeminal neuropathic pain. Orally active .
    Levomenol (Standard)
  • HY-14541A
    Olanzapine hydrochloride

    LY170053 hydrochloride

    		 5-HT Receptor Dopamine Receptor mAChR Adrenergic Receptor Autophagy Mitophagy Apoptosis Neurological Disease Cancer
    Olanzapine hydrochloride is a selective, orally active monoaminergic antagonist with high affinity binding to serotonin H1, 5HT2A/2C, 5HT3, 5HT6 (Ki=7, 4, 11, 57, and 5 nM, respectively), dopamine D1-4 (Ki=11 to 31 nM), muscarinic M1-5 (Ki=1.9-25 nM), and adrenergic α1 receptor (Ki=19 nM). Olanzapine hydrochloride is an atypical antipsychotic .
    Olanzapine hydrochloride
  • HY-14541
    Olanzapine
    5+ Cited Publications

    LY170053

    		 5-HT Receptor Dopamine Receptor mAChR Adrenergic Receptor Autophagy Mitophagy Apoptosis Neurological Disease Cancer
    Olanzapine (LY170053) is a selective, orally active monoaminergic antagonist with high affinity binding to serotonin H1, 5HT2A/2C, 5HT3, 5HT6 (Ki=7, 4, 11, 57, and 5 nM, respectively), dopamine D1-4 (Ki=11 to 31 nM), muscarinic M1-5 (Ki=1.9-25 nM), and adrenergic α1 receptor (Ki=19 nM). Olanzapine is an atypical antipsychotic .
    Olanzapine
  • HY-146619
    RAGE/SERT-IN-1

    		Amyloid-β Serotonin Transporter Neurological Disease
    RAGE/SERT-IN-1 is a potent and orally active advanced glycation end products (RAGE) and serotonin transporter (SERT) inhibitor with IC50s of 8.26 μM and 31.09 nM, respectively. RAGE/SERT-IN-1 exhibits significant neuroprotective effect against Aβ25-35-induced neuronal damage and alleviates depressive behavior of mice. RAGE/SERT-IN-1 can be used for researching the comorbidity of Alzheimer's disease and depression .
    RAGE/SERT-IN-1
  • HY-173307
    Nrf2 activator 19

    		Keap1-Nrf2 Apoptosis Reactive Oxygen Species Cardiovascular Disease
    Nrf2 activator 19 is a BBB-penetrable NRF2/HO-1 activator. Nrf2 activator 19 exerts potent antioxidant and neuroprotective effects. Nrf2 activator 19 can also effectively reduce brain damage, reduce Reactive Oxygen Species (ROS) accumulation. Nrf2 activator 19 inhibits neuronal apoptosis. Nrf2 activator 19 promotes the recovery of neurological function and motor ability. Nrf2 activator 19 shows significant potential in ischemic stroke research .
    Nrf2 activator 19
  • HY-163151
    JE-133

    		PI3K Akt p38 MAPK Neurological Disease Inflammation/Immunology
    JE-133 is an optically active isochromane-2H-chromene conjugate. JE-133 exhibits antioxidant and anti-inflammatory activities. JE-133 is a neuroprotective agent that effectively inhibits neuronal oxidative damage associated with PI3K/Akt and MAPK signaling pathways. JE-133 can also inhibit lipopolysaccharide (LPS) (HY-D1056)-induced neuroinflammation by regulating JAK/STAT and Nrf2 signaling pathways .
    JE-133
  • HY-159152
    PQM-164

    		α-synuclein Neurological Disease
    PQM-164 (Compound 3e) has antioxidant activity (IC50: 0.93 μM for DPPH radical). PQM-164 shows anti-inflammatory activity against 6-OHDA (HY-B1081A)-induced neuronal damage in activated microglial cells. PQM-164 decreases the accumulation of α-synuclein. PQM-164 promotes nuclear translocation of Nrf2 and its transcriptional activity. PQM-164 can be used for research of Parkinson’s disease .
    PQM-164
  • HY-N7046R
    Silybin B (Standard)

    Silibinin B (Standard)

    		 Reference Standards JNK Amyloid-β p38 MAPK Apoptosis Neurological Disease Cancer
    Silybin (Silibinin B) (Standard) is the analytical standard of Silybin B (HY-N7046). This product is intended for research and analytical applications. Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .
    Silybin B (Standard)
  • HY-N7046S
    Silybin B-d3

    Silibinin B-d3

    		 Isotope-Labeled Compounds Amyloid-β Apoptosis JNK p38 MAPK Neurological Disease Cancer
    Silybin B-d3 (Silibinin B-d3) is a deuterated Silybin B (HY-N7046). Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .
    Silybin B-d3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: